UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 14, 2014
RXi PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-54910 |
|
45-3215903 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 |
Results of Operations and Financial Condition. |
On May 14, 2014, RXi Pharmaceuticals Corporation
reported its results of operations for the quarter ended March 31, 2014. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the Report).
The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the
Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
|
|
|
99.1 |
|
Press Release dated May 14, 2014. |
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION |
|
|
|
|
Date: May 14, 2014 |
|
|
|
By: |
|
/s/ Geert Cauwenbergh |
|
|
|
|
|
|
Geert Cauwenbergh, Dr. Med. Sc. |
|
|
|
|
|
|
Chief Executive Officer |
Exhibit 99.1
RXi Pharmaceuticals Reports Financial
Results for the First Quarter of 2014
MARLBOROUGH, Mass., May 14, 2014 /PRNewswire/ RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on
discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the quarter ended March 31, 2014, and provided a business update.
The first quarter of 2014 has been one of steady progress in the clinical development of RXI-109, our sd-rxRNA®, for the treatment of fibrotic conditions of the skin, with our second Phase 2 study in keloids being initiated a few weeks ago, said Geert Cauwenbergh, President and CEO of RXI
Pharmaceuticals. He added that, the availability of the financing facility with Lincoln Park Capital, LLC has provided us with the necessary financial band width to accelerate the development of our ophthalmology franchise, which should yield
additional interesting data that could contribute to the growth of our company.
First Quarter 2014 and Recent Corporate Highlights
|
|
|
Announcement of Listing on The NASDAQ Capital Market: Announced in February 2014 that the Company received approval to list its common stock on The NASDAQ Capital Market. The Companys common stock
commenced trading under the same ticker symbol, RXII, on The NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014. |
|
|
|
Grant of Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders: In March 2014, the Company announced that it had been granted a patent by the U.S. Patent and Trademark Office on
its unique self-delivering RNAi compounds (sd-rxRNA), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF for the treatment of fibrotic disorders. The patent (U.S. Patent Number 8,664,189) is scheduled to expire in
2029. |
|
|
|
Entered into a Purchase Agreement with Lincoln Park Capital, LLC: Announced in April 2014 that the Company had entered into a purchase agreement with Lincoln Park Capital Fund, LLC (LPC), a
Chicago-based institutional investor, whereby LPC is committed to purchase up to an aggregate of $20 million of shares of the Companys common stock. Upon execution, LPC purchased 500,000 shares of common stock at $4.00 per share, for an
initial investment of $2 million. Upon the filing of the first investigational drug application for an ophthalmologic project with the U.S. Food and Drug Administration, LPC will make an additional $1 million share purchase at prevailing market
prices of the Companys common stock. In addition, at the sole discretion of the Company, we may sell up to $17 million worth of common stock to LPC over the 30-month term of the agreement. The funds, in part, will serve to advance research and
development activities for the Companys ophthalmological pre-clinical drug pipeline. |
Quarterly Financial Highlights
Cash and Cash Equivalents
At March 31, 2014,
RXi had cash, cash equivalents and short-term investments of approximately $12.0 million, compared with $14.4 million at December 31, 2013.
Net Loss
Net loss for the three months ended March 31, 2014 was $2.3 million, including $0.5 million in non-cash share-based compensation expense, compared with a
net loss of $14.4 million, including $0.6 million in non-cash share-based compensation expense, for the three months ended March 31, 2013. The decrease in net loss of $12.1 million was primarily attributable to a one-time charge of $12.3
million in the first quarter of 2013 related to the fair value of common shares issued to OPKO Health, Inc. (OPKO) for the purchase of substantially all of OPKOs RNAi-related assets.
Net Loss Applicable to Common Stockholders
Net
loss applicable to common stockholders for the three months ended March 31, 2014 was $4.0 million compared with a net loss applicable to common stockholders of $17.9 million for the comparable period in 2013. The decrease in net loss applicable
to common stockholders of $13.9 million was primarily attributable to the aforementioned decrease in net loss as compared to prior year and a decrease of $1.8 million in the fair value of dividends paid in additional preferred stock to the
Companys preferred shareholders.
Research and Development Expenses
Research and development expenses for the three months ended March 31, 2014 were $1.5 million, compared with $13.8 million for the three months ended
March 31, 2013. The decrease of $12.3 million is primarily related to the one-time charge of $12.3 million in the first quarter of 2013 related to the fair value of common shares issued to OPKO for the purchase of substantially all of
OPKOs RNAi-related assets.
General and Administrative Expenses
General and administrative expenses for the three months ended March 31, 2014 were $0.8 million, compared with $0.7 million for the three months ended
March 31, 2013. The increase of $0.1 million was due was primarily due to an increase in employee share-based compensation expense and an increase in general and administrative expenses due to listing fees incurred by the Company in connection
with the recent listing the on the NASDAQ Capital Market.
Preferred Stock Dividends
Preferred stock dividends were $1.8 million for the three months ended March 31, 2014, compared with $3.5 million for the comparable period in 2013. The
decrease of $1.7 million is due to due changes in the Companys closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter.
About RXi Pharmaceuticals Corporation
RXi
Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi
(sd-rxRNA®) platform. Therapeutics that use RNA interference, or RNAi, have great promise because of their ability to down-regulate the expression of specific genes that may be
over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the Companys Scientific Advisory Board, RXis first RNAi product candidate, RXI-109, entered
into human clinical trials in June 2012 and is currently in Phase 2. RXI-109 targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis). For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: intend, believe, expect,
may, should, designed to, will and similar references. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109 and our other product candidates;
the timing and future success of our clinical trials with RXI-109; our expectation that we will complete our Phase 2 clinical trials for RXI-109 within anticipated time periods and budgets; our ability to implement cost-saving measures and
statements about other future expectations. Forward-looking statements are neither historical facts nor assurances of future performance. Instead they are based only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the
forward-looking statements include, among others: the risk that our clinical trials with RXI-109 may not be successful in evaluating the continued safety and tolerability of RXI-109 or providing preliminary evidence of the reduction of formation of
surgical scars; the successful and timely completion of clinical studies; uncertainties regarding the regulatory process; the availability of funds and resources to pursue our research and development projects, including our clinical trials with
RXI-109; and those identified under Risk Factors in the Companys most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the SEC. The Company does not
undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
RXi PHARMACEUTICALS CORPORATION
(A Development Stage Company)
CONDENSED STATEMENTS OF
OPERATIONS
(Amounts in thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, 2014 |
|
|
For the Three Months Ended March 31, 2013 |
|
Total revenues |
|
$ |
29 |
|
|
$ |
53 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
|
1,476 |
|
|
|
13,771 |
|
General and administrative expenses |
|
|
843 |
|
|
|
676 |
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(2,290 |
) |
|
|
(14,394 |
) |
Interest income, net |
|
|
6 |
|
|
|
|
|
Other expense, net |
|
|
|
|
|
|
(3 |
) |
|
|
|
|
|
|
|
|
|
Net loss |
|
|
(2,284 |
) |
|
|
(14,397 |
) |
Series A and Series A-1 preferred stock dividends |
|
|
(1,755 |
) |
|
|
(3,547 |
) |
|
|
|
|
|
|
|
|
|
Net loss applicable to common stockholders |
|
$ |
(4,039 |
) |
|
$ |
(17,944 |
) |
|
|
|
|
|
|
|
|
|
Net loss per common share applicable to common stockholders: |
|
|
|
|
|
|
|
|
Basic and diluted loss per share |
|
$ |
(0.32 |
) |
|
$ |
(2.76 |
) |
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
12,616,086 |
|
|
|
6,496,095 |
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION
(A Development Stage Company)
CONDENSED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2014 |
|
|
December 31, 2013 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
9,010 |
|
|
$ |
11,390 |
|
Restricted cash |
|
|
50 |
|
|
|
50 |
|
Short-term investments |
|
|
3,000 |
|
|
|
3,000 |
|
Prepaid expenses and other current assets |
|
|
226 |
|
|
|
303 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
12,286 |
|
|
|
14,743 |
|
Equipment and furnishings, net |
|
|
155 |
|
|
|
177 |
|
Other assets |
|
|
18 |
|
|
|
18 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
12,459 |
|
|
$ |
14,938 |
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
277 |
|
|
$ |
163 |
|
Accrued expenses and other current liabilities |
|
|
1,024 |
|
|
|
1,795 |
|
Deferred revenue |
|
|
89 |
|
|
|
118 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
1,390 |
|
|
|
2,076 |
|
Total convertible preferred stock |
|
|
4,850 |
|
|
|
7,920 |
|
Total stockholders equity |
|
|
6,219 |
|
|
|
4,942 |
|
|
|
|
|
|
|
|
|
|
Total liabilities, convertible preferred stock and stockholders equity |
|
$ |
12,459 |
|
|
$ |
14,938 |
|
|
|
|
|
|
|
|
|
|
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Apr 2023 to Apr 2024